Medical Devices Series B Investors & VC Firms
660 firms in this list, with a median first check of $730K. 140 of them lead rounds. Generated from verified public data and updated continuously.
Forbion
NaardenPre-Seed–Late Stage
24 people
Hadean Ventures
OsloSeed–Growth
21 people
Lauder Partners
Los AltosSeries B
1 person
Sunstone Capital
FrederiksbergPre-Seed–Series B
13 people
TVM Capital
MunichSeed–Late Stage$1.1M – $16.2M
22 people
Inkef
AmsterdamSeed–Growth
14 people
Oncology Ventures
New YorkSeed–Series B
18 people
Starquest Capital
ParisSeed–Growth$530K – $21.2M
14 people
Big Pi Ventures
AthensPre-Seed–Growth$540K – $3.2M
19 people
Venture Ontario
TorontoSeed–Growth
3 people
BRM Capital
Tel AvivSeed–Late Stage$1.7M – $28M
14 people
Maverick Ventures Israel
Tel AvivSeed–Series B$2M – $5M
11 people
Sixty Degree Capital
North YorkPre-Seed–Late Stage
19 people
California Technology Ventures
PasadenaSeed–Late Stage$250K – $2M
3 people
Hiroshima Venture Capital Co. Ltd.
HiroshimaPre-Seed–Late Stage
GSR United Capital
BeijingSeed–Late Stage$98K – $50M
Necessary Ventures
San FranciscoPre-Seed–Late Stage$1M – $2M
10 people
Planven Entrepreneur Ventures
ZurichSeed–Late Stage$10M – $20M
18 people
Lilly Asia Ventures
Hong KongPre-Seed–Late Stage
1 person
Limburgse Reconversie Maatschappij
HasseltSeed–Late Stage$27K – $10.8M
22 people
New Alliance Capital
ShanghaiSeed–Late Stage
25 people
Sciety
StockholmSeed–Growth
21 people
Fast Track Initiative
TokyoPre-Seed–Growth$1.2M – $184M
2 people
MedTech Actuator
Seed–Series B
Related lists
Series B Investors & VC Firms (4094)Series B Investors & VC Firms in United States (1625)Medical Devices Investors & VC Firms (1393)SaaS Series B Investors & VC Firms (1317)Series B Investors & VC Firms in Global (1265)Enterprise Software Series B Investors & VC Firms (1242)Healthtech Series B Investors & VC Firms (1216)Medical Devices Seed Investors & VC Firms (1155)Medical Devices Series A Investors & VC Firms (1145)Fintech Series B Investors & VC Firms (1141)
Data sourced from public filings and firms' own websites — see our methodology.


























































